tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MLYS Stock Latest News

3 Best Stocks to Buy Now, 7/15/2025, According to Top Analysts
Market News3 Best Stocks to Buy Now, 7/15/2025, According to Top Analysts
24d ago
MLYS
PRAX
Promising Investment Opportunity in Mineralys Therapeutics Driven by Lorundrostat’s Clinical Success
PremiumRatings
Promising Investment Opportunity in Mineralys Therapeutics Driven by Lorundrostat’s Clinical Success
25d ago
MLYS
Mineralys Therapeutics announces publication of Phase 3 Launch-HTN trial results
PremiumThe Fly
Mineralys Therapeutics announces publication of Phase 3 Launch-HTN trial results
1M ago
MLYS
Promising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment Appeal
PremiumRatings
Promising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment Appeal
2M ago
MLYS
Positive Phase II Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating
PremiumRatings
Positive Phase II Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating
2M ago
MLYS
Promising Phase 2 Trial Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating and $42 Price Target
PremiumRatingsPromising Phase 2 Trial Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating and $42 Price Target
2M ago
MLYS
Mineralys Therapeutics Reports Positive Phase 2 Trial Results
Premium
Company Announcements
Mineralys Therapeutics Reports Positive Phase 2 Trial Results
2M ago
8K
MLYS
Mineralys announces its Phase 2 Explore-CKD trial met primary endpoint
Premium
The Fly
Mineralys announces its Phase 2 Explore-CKD trial met primary endpoint
2M ago
MLYS
Cautious Outlook for Mineralys Therapeutics Amid Market Challenges and Competitive Pressures
PremiumRatings
Cautious Outlook for Mineralys Therapeutics Amid Market Challenges and Competitive Pressures
2M ago
MLYS
Mineralys Therapeutics initiated with a Hold at Jefferies
PremiumThe Fly
Mineralys Therapeutics initiated with a Hold at Jefferies
2M ago
AZN
MLYS
3 Best Stocks to Buy Now, 5/27/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 5/27/2025, According to Top Analysts
2M ago
UAL
AKRO
Buy Rating for Mineralys Therapeutics: Strong Clinical Results and Growth Prospects Highlight Significant Upside Potential
PremiumRatings
Buy Rating for Mineralys Therapeutics: Strong Clinical Results and Growth Prospects Highlight Significant Upside Potential
2M ago
MLYS
Mineralys announces late-breaking presentation of data from Launch-HTN trial
PremiumThe FlyMineralys announces late-breaking presentation of data from Launch-HTN trial
2M ago
MLYS
Mineralys Therapeutics Approves Key Proposals at Annual Meeting
Premium
Company Announcements
Mineralys Therapeutics Approves Key Proposals at Annual Meeting
3M ago
8K
MLYS
Mineralys Therapeutics’ Earnings Call: Positive Outlook Amid Challenges
Premium
Company Announcements
Mineralys Therapeutics’ Earnings Call: Positive Outlook Amid Challenges
3M ago
MLYS
Mineralys Therapeutics price target lowered to $48 from $52 at Guggenheim
PremiumThe Fly
Mineralys Therapeutics price target lowered to $48 from $52 at Guggenheim
3M ago
MLYS
3 Best Stocks to Buy Now, 5/14/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 5/14/2025, According to Top Analysts
3M ago
APP
MLYS
Strong Financial Position and Promising Clinical Results Support Buy Rating for Mineralys Therapeutics
PremiumRatings
Strong Financial Position and Promising Clinical Results Support Buy Rating for Mineralys Therapeutics
3M ago
MLYS
Positive Buy Rating for Lorundrostat Driven by Successful Trials and Future Potential
PremiumRatings
Positive Buy Rating for Lorundrostat Driven by Successful Trials and Future Potential
3M ago
MLYS
Optimistic Buy Rating for Mineralys Therapeutics Driven by Strategic Developments and Upcoming Data Releases
PremiumRatingsOptimistic Buy Rating for Mineralys Therapeutics Driven by Strategic Developments and Upcoming Data Releases
3M ago
MLYS
Mineralys Therapeutics Reports Strong Trial Results and Financial Growth
Premium
Company Announcements
Mineralys Therapeutics Reports Strong Trial Results and Financial Growth
3M ago
MLYS
Mineralys Therapeutics reports Q1 EPS (79c), consensus (98c)
Premium
The Fly
Mineralys Therapeutics reports Q1 EPS (79c), consensus (98c)
3M ago
MLYS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >